{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:16:17Z","timestamp":1792700177344,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003232.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000}}],"reference-count":301,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003232.pub4","type":"journal-article","created":{"date-parts":[[2020,1,12]],"date-time":"2020-01-12T23:32:30Z","timestamp":1578871950000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Interventions for renal vasculitis in adults"],"prefix":"10.1002","volume":"2020","author":[{"given":"Giles D","family":"Walters","sequence":"first","affiliation":[{"name":"The Canberra Hospital; Department of Renal Medicine; Yamba Drive Canberra ACT Australia 2605"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narelle S","family":"Willis","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess E","family":"Cooper","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145"},{"name":"Flinders University; College of Medicine and Public Health; Adelaide SA Australia 5001"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD003232.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/qjmed\/90.6.401","article-title":"Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis","volume":"90","author":"Adu","year":"1997","journal-title":"Qjm"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0002|cit2","first-page":"317","article-title":"Controlled trial of pulse cyclophosphamide (PCY) and prednisolone (PP) versus continuous cyclophosphamide (CCY) and prednisolone (CP) in the treatment of systemic vasculitis [abstract]","volume":"3","author":"Pall","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003232.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ndt\/gfw211","article-title":"Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial","volume":"31","author":"Sanders","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0004|cit4","unstructured":"Boomsma MM Stegeman CA Hermans J Kallenberg CG Hene RJ Limburg PC Prevention of relapses in PR3 anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis by treatment with azathioprine and corticosteroids: a multi-centre, randomized study [abstract no: 020] 11th International Vasculitis & ANCA Workshop; 2003 Oct 2-5; Prague, Czech Republic 2003 29 30"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003232.pub4-BIB0005|cit5","first-page":"347","article-title":"Prevention of relapses in PR3 anti-neutrophil cytoplasmic antibody associated vasculitis by treatment with azathioprine and corticosteroids: a multi-centre, randomized study [abstract no: T208]","volume":"18","author":"Boomsma","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0006|cit6","first-page":"1488","article-title":"Belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: effect on biomarkers [abstract]","volume":"77","author":"Jayne","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD003232.pub4-BIB0007|cit7","first-page":"NA","article-title":"Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: a multicenter randomized, placebo-controlled study [abstract no: 893]","volume":"69","author":"Jayne","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD003232.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/art.40802","article-title":"Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD003232.pub4-BIB0009|cit9","first-page":"S820","article-title":"CCX168, an orally administered C5aR inhibitor for treatment of patients with antineutrophil cytoplasmic antibody-associated vasculitis [abstract no: 1863]","volume":"66","author":"Bekker","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0010|cit10","first-page":"ii419","article-title":"Oral C5A receptor antagonist CCX168 in a phase 2 clinical trial in ANCA-associated renal vasculitis [abstract]","volume":"27","author":"Bekker","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0011|cit11","first-page":"788A","article-title":"Phase 2 clinical trial of CCX168, an orally administered C5aR antagonist, in patients with ANCA-associated renal vasculitis (CLEAR) [abstract no: SA-PO695]","volume":"24","author":"Bruchfeld","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.lpm.2013.02.277","article-title":"C5aR inhibitor on leukocytes exploratory ANCA associated renal vasculitis (CLEAR) clinical trial with orally administered CCX168 [abstract no: P206]","volume":"42","author":"Bruchfeld","year":"2013","journal-title":"Presse Medicale"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0013|cit13","first-page":"74","article-title":"Effect of a selective C5AR antagonist, avacopan (CCX168), on plasma complement levels in ANCA associated vasculitis (AAV) [abstract]","volume":"77","author":"Bunch","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003232.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"i45","DOI":"10.1093\/ndt\/gfw137.01","article-title":"Successful steroid replacement in ANCA-associated vasculitis with c5a receptor inhibitor CCX168 in phase 2 randomised trial (CLEAR) [abstract no: MO039]","volume":"31","author":"Jayne","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003232.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"i85","DOI":"10.1093\/ndt\/gfy104.FP167","article-title":"Adverse events with glucocorticoid standard of care versus avacopan in ANCA-associated vasculitis: observations from the CLEAR trial [abstract]","volume":"33","author":"Jayne","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003232.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"iii27","DOI":"10.1093\/ndt\/gfu120","article-title":"Phase 2 randomised trial of oral C5A receptor antagonist CCX168 in ANCA-associated renal vasculitis [abstract]","volume":"29","author":"Jayne","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD003232.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003232.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"iii27","DOI":"10.1093\/ndt\/gfu120","article-title":"Phase 2 randomised trial of oral C5A receptor antagonist CCX168 in ANCA-associated renal vasculitis [abstract no: MO012]","volume":"29","author":"Jayne","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/j.ajkd.2018.02.272","article-title":"C5ar inhibitor avacopan in anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis phase II outcomes of safety, renal parameters, and quality of life [abstract]","volume":"71","author":"Schall","year":"2018","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003232.pub4-BIB0020|cit20","first-page":"9A","article-title":"Rapid onset of orally administered C5aR inhibitor CCX168 in randomized clinical trial in ANCA-associated vasculitis (CLEAR) [abstract no: TH-OR037]","volume":"27","author":"Tesar","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0272-6386(12)80699-8","article-title":"A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group","volume":"20","author":"Cole","year":"1992","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003232.pub4-BIB0023|cit23","first-page":"63","article-title":"Baseline data and interim induction analysis based on the 101 patients aged \u2265 65 years with SNV enrolled in the CORTAGE multi-centre trial [abstract]","volume":"164","author":"Pagnoux","year":"2011","journal-title":"Clinical & Experimental Immunology"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0024|cit24","first-page":"189","article-title":"Demographic data in ANCA associated vasculitis [abstract no: 90]","volume":"28","author":"Flossmann","year":"2005","journal-title":"Kidney & Blood Pressure Research"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0025|cit25","first-page":"554A","article-title":"Demographic data in ANCA associated vasculitis [abstract no: F-PO998]","volume":"16","author":"Flossmann","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD003232.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"e0165402","DOI":"10.1371\/journal.pone.0165402","article-title":"ANCA-associated glomerulonephritis: risk factors for renal relapse","volume":"11","author":"Goceroglu","year":"2016","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.bor.0000160777.28259.c2","article-title":"Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies","volume":"17","author":"Goek","year":"2005","journal-title":"Current Opinion in Rheumatology"},{"issue":"Oct","key":"10.1002\/14651858.CD003232.pub4-BIB0028|cit28","first-page":"360A","article-title":"Adverse events in patients with primary systemic vasculitis [abstract no: SA-PO271]","volume":"15","author":"Harper","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003232.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1046\/j.1523-1755.2002.00605.x","article-title":"Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients","volume":"62","author":"Hauer","year":"2002","journal-title":"Kidney International"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003232.pub4-BIB0030|cit30","first-page":"105A","article-title":"Randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (CYCAZAREM) [abstract no: A0540]","volume":"10","author":"Jayne","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0032|cit32","unstructured":"Jayne DR Pusey CD European Vasculitis Study Group (EUVAS) European randomised trials in ANCA-associated systemic vasculitis: a progressive report [abstract] 35th Congress of the European Renal Association European Dialysis & Transplant Association; 1998 Jun 6-9; Rimini (Italy) 1998 106"},{"issue":"5","key":"10.1002\/14651858.CD003232.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/rheumatology\/keu357","article-title":"Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials","volume":"54","author":"Rahmattulla","year":"2015","journal-title":"Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD003232.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/rheumatology\/kex001","article-title":"Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate","volume":"56","author":"Salmela","year":"2017","journal-title":"Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD003232.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/rheumatology\/ker266","article-title":"Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials","volume":"50","author":"Suppiah","year":"2011","journal-title":"Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0036|cit36","first-page":"199","article-title":"Optimizing the therapeutic strategies in ANCA-associated vasculitis--single centre experience with international randomized trials","volume":"107","author":"Vankova","year":"2006","journal-title":"Prague Medical Report"},{"issue":"9","key":"10.1002\/14651858.CD003232.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2215\/CJN.00100114","article-title":"Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis","volume":"9","author":"Walsh","year":"2014","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Harper L Morgan M Flossman O Westman K de Groot K Flores Suarez LF Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis [abstract no: 079] Renal Association & British Renal Society Joint Meeting; 2011 Jun 6-9; Birmingham, UK 2011 908","DOI":"10.1136\/annrheumdis-2011-200477"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003232.pub4-BIB0039|cit39","first-page":"56","article-title":"Pulse versus daily oral CyP for induction of remission in ANCA-associated vasculitis. A European, multi-centre randomized controlled trial: long-term follow up [abstract]","volume":"164","author":"Harper","year":"2011","journal-title":"Clinical & Experimental Immunology"},{"issue":"6","key":"10.1002\/14651858.CD003232.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0041|cit41","first-page":"115","article-title":"Remaining anti-neutrophil cytoplasm antibody positive at switch to maintenance therapy is associated with an increased risk of relapse: observation from the long term follow up of the CYCLOPS and IMPROVE trials [abstract no: P20]","volume":"129","author":"Morgan","year":"2015","journal-title":"Nephron"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-017-1321-1","article-title":"Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse","volume":"19","author":"Morgan","year":"2017","journal-title":"Arthritis Research & Therapy"},{"issue":"5","key":"10.1002\/14651858.CD003232.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/rheumatology\/keu357","article-title":"Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials","volume":"54","author":"Rahmattulla","year":"2015","journal-title":"Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0044|cit44","first-page":"64","article-title":"Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis--preliminary single center experience","volume":"105","author":"Rihova","year":"2004","journal-title":"Prague Medical Report"},{"issue":"12","key":"10.1002\/14651858.CD003232.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/rheumatology\/ker266","article-title":"Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials","volume":"50","author":"Suppiah","year":"2011","journal-title":"Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD003232.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"Groot","year":"2009","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0047|cit47","first-page":"7A","article-title":"European, multicenter randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA-associated systemic vasculitis [abstract no: TH-FC033]","volume":"16","author":"Groot","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0048|cit48","first-page":"195","article-title":"Randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA-associated systemic vasculitis [abstract no: 103]","volume":"28","author":"Groot","year":"2005","journal-title":"Kidney & Blood Pressure Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003232.pub4-BIB0049|cit49","first-page":"S127","article-title":"Lymphocytapheresis (LCP) in rapidly progressive glomerulonephritis (RPGN) a comparison with steroid pulse therapy [abstract no: P208]","volume":"3","author":"Furuta","year":"1997","journal-title":"Nephrology"},{"issue":"9123","key":"10.1002\/14651858.CD003232.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(05)77809-0","article-title":"Lymphocytapheresis to treat rapidly progressive glomerulonephritis: a randomised comparison with steroid-pulse treatment","volume":"352","author":"Furuta","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0051|cit51","first-page":"1","article-title":"Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multi-center study","volume":"29","author":"Glockner","year":"1988","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/rheumatology\/40.2.147","article-title":"Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study","volume":"40","author":"Girard","year":"2001","journal-title":"Rheumatology"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD003232.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.lpm.2006.11.025","article-title":"Long-term outcome of 37 patients with Wegener's granulomatosis with renal involvement","volume":"36","author":"Gottenberg","year":"2007","journal-title":"Presse Medicale"},{"issue":"12","key":"10.1002\/14651858.CD003232.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis","volume":"40","author":"Guillevin","year":"1997","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl II","key":"10.1002\/14651858.CD003232.pub4-BIB0055|cit55","first-page":"SII","article-title":"Treatment of polyarteritis nodosa (PAN) and microscopic polyangiitis (MPA) with poor prognosis factors: a prospective trial comparing steroids (CS) and 6 or 12 cyclophosphamide (CYC) pulses in 65 patients [abstract no: 112-113]","volume":"69","author":"Guillevin","year":"2002","journal-title":"Cleveland Clinic Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.10922","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients","volume":"49","author":"Guillevin","year":"2003","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000324364","article-title":"Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis","volume":"33","author":"Han","year":"2011","journal-title":"American Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0058|cit58","first-page":"922","article-title":"ANCA-associated vasculitis and renal involvement: preliminary results of a prospective randomised study comparing daily oral versus monthly I.V. cyclophosphamide application [abstract]","volume":"6","author":"Haubitz","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD003232.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q","article-title":"Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study","volume":"41","author":"Haubitz","year":"1998","journal-title":"Arthritis & Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ndt\/gfm780","article-title":"Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement","volume":"23","author":"Hu","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0061|cit61","unstructured":"Hiemstra T Walsh M Andrews P Short A Savage C Harper L Randomized controlled trial of mycophenolate mofetil versus azathioprine for maintenance therapy in ANCA-associated vasculitis (IMPROVE) [abstract no: O23] British Renal Society Conference; 2010 May 17-May 20; Manchester, UK 2010"},{"issue":"21","key":"10.1002\/14651858.CD003232.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003232.pub4-BIB0063|cit63","first-page":"77A","article-title":"Randomised controlled trial of mycophenolate mofetil versus azathioprine for maintenance therapy in ANCA associated vasculitis (IMPROVE) [abstract no: SA-FC331]","volume":"20","author":"Hiemstra","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0064|cit64","unstructured":"IMPROVE Co-ordinators International mycophenolate mofetil protocol to reduce outbreaks of vasculitides (IMPROVE) www.vasculitis.org\/images\/documents\/improve.pdf"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-017-1321-1","article-title":"Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse","volume":"19","author":"Morgan","year":"2017","journal-title":"Arthritis Research & Therapy"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0066|cit66","unstructured":"Schmitt WH Jayne D Van der Woude FJ European Vasculitis Study Group (EUVAS) Mycophenolate mofetil (MMF) vs azathioprine (AZA) for the maintenance of remission in ANCA-associated vasculitis: the IMPROVE protocol [abstract no: P90] 11th International Vasculitis & ANCA Workshop; 2003 Oct 2-5; Prague, Czech Republic 2003 51"},{"issue":"7","key":"10.1002\/14651858.CD003232.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"Qjm"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003232.pub4-BIB0068|cit68","first-page":"iii28","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. A prospective study in 117 patients [abstract]","volume":"29","author":"Guillevin","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"19","key":"10.1002\/14651858.CD003232.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0070|cit70","first-page":"S706","article-title":"Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis [abstract]","volume":"64","author":"Guillevin","year":"2012","journal-title":"Arthritis & Rheumatism"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0071|cit71","first-page":"S314","article-title":"Relationship between infectious side effects and immunoglobulin levels in the maintenance rituximab vs azathioprine for ANCA-associated vasculitides [abstract no: 744]","volume":"65","author":"Guillevin","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD003232.pub4-BIB0072|cit72","first-page":"na","article-title":"Economic evaluation of rituximab versus azathioprine for maintenance treatment of ANCA-associated vasculitis. A prospective, multicenter study [abstract]","volume":"69","author":"Montante","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0073|cit73","first-page":"S780","article-title":"Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact in health-related quality of life [abstract no: 1778]","volume":"66","author":"Pugnet","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"3 Suppl 97","key":"10.1002\/14651858.CD003232.pub4-BIB0074|cit74","first-page":"S54","article-title":"Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life","volume":"34","author":"Pugnet","year":"2016","journal-title":"Clinical & Experimental Rheumatology"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0075|cit75","first-page":"S779","article-title":"Factors predictive of ANCA-associated vasculitis relapse in patients given rituximab-maintenance therapy [abstract no: 1776]","volume":"66","author":"Terrier","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0076|cit76","first-page":"55","article-title":"Factors predictive of ANCA-associated vasculitis relapse in patients given rituximab-maintenance therapy: data from the extended follow-up of MAINRITSAN trial patients [abstract no: O19]","volume":"129","author":"Terrier","year":"2015","journal-title":"Nephron"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.lpm.2013.02.301","article-title":"Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (MAINRITSAN): Follow-up at 34 months [abstract no: P230]","volume":"42","author":"Terrier","year":"2013","journal-title":"Press Medicale"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003232.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"A124","DOI":"10.1136\/annrheumdis-2013-eular.418","article-title":"Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (MAINRITSAN): follow up at 34 months [abstract no: OP0213]","volume":"72","author":"Terrier","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0079|cit79","first-page":"S1190","article-title":"Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies-associated vasculitis: follow up at 39 months [abstract no: 2783]","volume":"65","author":"Terrier","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD003232.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003232.pub4-BIB0081|cit81","first-page":"iii16","article-title":"Rituximab versus azathioprine to maintain remission of ANCA-associated vasculitides (MAINRITSAN): Follow-up at 60 months [abstract]","volume":"56","author":"Terrier","year":"2017","journal-title":"Rheumatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0082|cit82","first-page":"na","article-title":"Reducing the number of rituximab infusions at onset of maintenance therapy for ANCA-associated vasculitides: results of a post hoc analysis from a randomized-controlled trials [abstract]","volume":"58","author":"Charles","year":"2019","journal-title":"Rheumatology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003232.pub4-BIB0083|cit83","first-page":"iii151","article-title":"Comparison of systematic vs individually tailored rituximab regimen to maintain ANCA associated vasculitis remission [abstract]","volume":"56","author":"Charles","year":"2017","journal-title":"Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD003232.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).[Erratum appears in: Ann Rheum Dis. 2019 Sep;78(9):e101; PMID: 31405899]","volume":"77","author":"Charles","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD003232.pub4-BIB0085|cit85","article-title":"Comparison of individually tailored vs systematic rituximab regimens to maintain ANCA-associated vasculitis remissions: results of a prospective, randomized-controlled, phase 3 trial [abstract]","volume":"69","author":"Charles","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD003232.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"e0185880","DOI":"10.1371\/journal.pone.0185880","article-title":"Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial","volume":"12","author":"Maritati","year":"2017","journal-title":"PLoS ONE [Electronic Resource]"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0087|cit87","unstructured":"Vaglio A Casazza I Grasselli C Alberici F Palmisano A Andrulli S Methotrexate versus cyclophosphamide as maintenance therapy for ANCA-associated vasculitides [abstract no: M318] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0088|cit88","first-page":"587","article-title":"Therapeutic plasma exchange in the treatment of rapidly progressive glomerulonephritis","volume":"6","author":"Mauri","year":"1985","journal-title":"Plasma Therapy & Transfusion Technology"},{"issue":"2 (Pt II)","key":"10.1002\/14651858.CD003232.pub4-BIB0089|cit89","first-page":"A39","article-title":"Evaluation of plasma exchanges (PEX) in the treatment of rapidly progressive glomerulonephritis (RPGN) preliminary results of a randomized trial [abstract no: 231]","volume":"15","author":"Mauri","year":"1985","journal-title":"European Journal of Clinical Investigation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003232.pub4-BIB0090|cit90","first-page":"52","article-title":"Plasma exchange for severe renal vasculitis: long-term follow-up of the MEPEX trial [abstract]","volume":"164","author":"Casian","year":"2011","journal-title":"Clinical & Experimental Immunology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0091|cit91","first-page":"70A","article-title":"A long-term analysis of the MEPEX trial: plasma exchange for severe renal ANCA vasculitis [abstract no: FR-OR290]","volume":"22","author":"Casian","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0092|cit92","first-page":"189","article-title":"Demographic data in ANCA associated vasculitis [abstract no: 90]","volume":"28","author":"Flossmann","year":"2005","journal-title":"Kidney & Blood Pressure Research"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003232.pub4-BIB0093|cit93","first-page":"554A","article-title":"Demographic data in ANCA associated vasculitis [abstract]","volume":"16","author":"Flossmann","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Programs & Abst","key":"10.1002\/14651858.CD003232.pub4-BIB0094|cit94","first-page":"2A","article-title":"Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis [abstract no: F-FC010]","volume":"13","author":"Gaskin","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD003232.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"e0165402","DOI":"10.1371\/journal.pone.0165402","article-title":"ANCA-associated glomerulonephritis: risk factors for renal relapse","volume":"11","author":"Goceroglu","year":"2016","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"Oct","key":"10.1002\/14651858.CD003232.pub4-BIB0096|cit96","first-page":"360A","article-title":"Adverse events in patients with primary systemic vasculitis [abstract no: SA-PO271]","volume":"15","author":"Harper","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD003232.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0098|cit98","unstructured":"Jayne DR Pusey CD European Vasculitis Study Group (EUVAS) European randomised trials in ANCA-associated systemic vasculitis: a progressive report [abstract] 35th Congress of the European Renal Association European Dialysis & Transplant Association; 1998 Jun 6-9; Rimini, Italy 1998 106"},{"issue":"8","key":"10.1002\/14651858.CD003232.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0025-6196(11)63594-5","article-title":"Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group","volume":"72","author":"Jayne","year":"1997","journal-title":"Mayo Clinic Proceedings"},{"issue":"5","key":"10.1002\/14651858.CD003232.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/rheumatology\/keu357","article-title":"Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials","volume":"54","author":"Rahmattulla","year":"2015","journal-title":"Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD003232.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/rheumatology\/ker266","article-title":"Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials","volume":"50","author":"Suppiah","year":"2011","journal-title":"Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0102|cit102","first-page":"199","article-title":"Optimizing the therapeutic strategies in ANCA-associated vasculitis--single centre experience with international randomized trials","volume":"107","author":"Vankova","year":"2006","journal-title":"Prague Medical Report"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2013.131","article-title":"Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear","volume":"84","author":"Walsh","year":"2013","journal-title":"Kidney International"},{"issue":"Oct","key":"10.1002\/14651858.CD003232.pub4-BIB0104|cit104","first-page":"340A","article-title":"Determinants of outcome in ANCA-associated vasculitis: a prospective clinico-histopathological analysis of 65 patients [abstract no: SA-PO183]","volume":"15","author":"Lind van Wijngaarden","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD003232.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1681\/ASN.2007010066","article-title":"Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis","volume":"18","author":"Lind van Wijngaarden","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD003232.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1681\/ASN.2005080870","article-title":"Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement","volume":"17","author":"Lind van Wijngaarden","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0107|cit107","first-page":"677A","article-title":"Predictors of outcome in severe ANCA-associated glomerulonephritis [abstract no: SA-PO551]","volume":"16","author":"Lind van Wijngaarden","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0108|cit108","first-page":"52A","article-title":"Treatment decisions in severe ANCA-associated glomerulonephritis [abstract no: F-FC063]","volume":"16","author":"Lind van Wijngaarden","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0109|cit109","first-page":"196","article-title":"Unexpected high relapse-rate under oral methotrexate for maintenance of remission in Wegener's granulomatosis. The LEM-trial comparing leflunomide versus methotrexat [abstract no: 106]","volume":"28","author":"Metzler","year":"2005","journal-title":"Kidney & Blood Pressure Research"},{"issue":"7","key":"10.1002\/14651858.CD003232.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","article-title":"Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis","volume":"46","author":"Metzler","year":"2007","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0111|cit111","unstructured":"Jayne D Jones R Harper L MYCYC clinical trial protocol: A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis [protocol Version 2A, 16th January 2007] www.vasculitis.org\/images\/documents\/mycyc.pdf"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0112|cit112","unstructured":"Jones R Harper L Brogan P Dahisveen K Lanyon P Jayne D A randomised trial of mycophenolate mofetil versus cyclosphosphamide for remission induction of ANCA-associated vasculitis: MYCYC [abstract no: O4] British Transplantation Society & the Renal Association Joint Congress; 2013 Mar 13-15; Bournemouth, UK 2013"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003232.pub4-BIB0113|cit113","first-page":"3B","article-title":"A randomised trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: MYCYC [abstract no: HI-OR04]","volume":"23","author":"Jones","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0114|cit114","first-page":"2B","article-title":"18 month results from a randomised trial of mycophenolate mofetil versus cyclophosphamide for remission induction of severe ANCA-associated vasculitis: MYCYC [abstract no: SA-PO1077]","volume":"24","author":"Jones","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD003232.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Groot","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD003232.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/art.34547","article-title":"Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Faurschou","year":"2012","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.bor.0000160777.28259.c2","article-title":"Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies","volume":"17","author":"Goek","year":"2005","journal-title":"Current Opinion in Rheumatology"},{"issue":"1 Suppl 75","key":"10.1002\/14651858.CD003232.pub4-BIB0119|cit119","first-page":"S38","article-title":"Changes in proteinase 3 anti-neutrophil cytoplasm autoantibody levels in early systemic granulomatosis with polyangiitis (Wegener's) may reflect treatment rather than disease activity","volume":"31","author":"Rasmussen","year":"2013","journal-title":"Clinical & Experimental Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD003232.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/rheumatology\/kex001","article-title":"Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate","volume":"56","author":"Salmela","year":"2017","journal-title":"Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD003232.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/rheumatology\/ker266","article-title":"Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials","volume":"50","author":"Suppiah","year":"2011","journal-title":"Rheumatology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003232.pub4-BIB0122|cit122","first-page":"2A","article-title":"Randomised trial of cyclophosphamide versus methotrexate for induction of remission in 'non-renal' ANCA-associated vasculitis [abstract no: F-FC009]","volume":"13","author":"Groot","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0123|cit123","unstructured":"Casian A Merkel P Walsh M Jayne D PEXIVAS: design of a randomised controlled trial of plasma exchange and glucocorticoid dosing in severe ANCA associated vasculitis [abstract no: P259] Renal Association & British Renal Society Joint Meeting; 2010 May 17-20; Manchester, UK 2010 363"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0124|cit124","unstructured":"European Vasculitis Study Group (EUVAS) and the Vasculitis Clinical Research Consortium (VCRC) Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: an international randomized controlled trial (Protocol Version: 1.1). 2010 www.vasculitis.org\/images\/pexivas201.120protocol.pdf"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003232.pub4-BIB0125|cit125","first-page":"iii150","article-title":"Demographic characteristics of Japanese participants in PEXIVAS as compared with REMIT-JAV [abstract]","volume":"56","author":"Kono","year":"2017","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003232.pub4-BIB0126|cit126","first-page":"67","article-title":"PEXIVAS: design of an RCT of PLEX and GC dosing in the treatment of severe ANCA-AAV [abstract]","volume":"164","author":"Walsh","year":"2011","journal-title":"Clinical & Experimental Immunology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003232.pub4-BIB0127|cit127","first-page":"iii149","article-title":"Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: Baseline characteristics of a randomized controlled trial (PEXIVAS) [abstract]","volume":"56","author":"Walsh","year":"2017","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003232.pub4-BIB0128|cit128","first-page":"1636","article-title":"The effect of plasma exchange on end stage renal disease and death in patients with severe ANCA associated vasculitis [abstract no: LB01]","volume":"33","author":"Walsh","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0129|cit129","first-page":"59","article-title":"The effect of plasma exchange and the effect of reduced-dose oral glucocorticoids during remission induction in severe ANCA-Associated vasculitis [abstract no: FR-OR079]","volume":"29","author":"Walsh","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0130|cit130","first-page":"73","article-title":"Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial","volume":"14","author":"Walsh","year":"2013","journal-title":"Trials [Electronic Resource]"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/ki.1991.272","article-title":"Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies","volume":"40","author":"Pusey","year":"1991","journal-title":"Kidney International"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD003232.pub4-BIB0132|cit132","first-page":"na","article-title":"B-cell depletion by rituximab affects the distribution of effector th-cell subsets in patients with ANCA associated vasculitis [abstract]","volume":"69","author":"Abdulahad","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD003232.pub4-BIB0133|cit133","first-page":"na","article-title":"Circulating cytokine profiles reflect ANCA specificity in patients with ANCA-associated vasculitis [abstract]","volume":"69","author":"Berti","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0134|cit134","first-page":"771","article-title":"Serum interleukin-6 levels in antineutrophil cytoplasmic antibody-associated vasculitis [abstract]","volume":"77","author":"Berti","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0135|cit135","first-page":"96","article-title":"Association of Fc gamma receptor polymorphisms and outcomes in patients with ANCA-associated vasculitis treated with rituximab [abstract no: O84]","volume":"129","author":"Cartin-Ceba","year":"2015","journal-title":"Nephron"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003232.pub4-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.lpm.2013.02.080","article-title":"The association of IgM ANCA and alveolar hemorrhage revisited [abstract no: P9]","volume":"42","author":"Clain","year":"2013","journal-title":"Presse Medicale"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/rheumatology\/kex484","article-title":"Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis","volume":"57","author":"Cornec","year":"2018","journal-title":"Rheumatology"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0138|cit138","first-page":"S818","article-title":"Serum calprotectin and disease relapse in ANCA-associated vasculitis [abstract no: 1860]","volume":"66","author":"Draibe","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0139|cit139","first-page":"113","article-title":"Predictive value of a rise in PR3-ANCA for relapse after complete remission in severe ANCA-associated vasculitis [abstract no: P17]","volume":"129","author":"Fussner","year":"2015","journal-title":"Nephron"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD003232.pub4-BIB0140|cit140","first-page":"S660","article-title":"The efficacy of rituximab vs cyclophosphamide for the treatment of renal disease in ANCA-associated vasculitis: the RAVE trial [abstract no: 1542]","volume":"64","author":"Geetha","year":"2012","journal-title":"Arthritis & Rheumatism"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003232.pub4-BIB0141|cit141","first-page":"88A","article-title":"The efficacy of rituximab versus cyclophosphamide for treatment of renal disease in ANCA-associated vasculitis: the RAVE Trial [abstract no: SA-OR099]","volume":"23","author":"Geetha","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000480443","article-title":"Interstitial immunostaining and renal outcomes in antineutrophil cytoplasmic antibody-associated glomerulonephritis","volume":"46","author":"Geetha","year":"2017","journal-title":"American Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0144|cit144","first-page":"108","article-title":"MabThera\u00ae (Rituximab) for the treatment of severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) - a cost-utility model for the United Kingdom [abstract no: P9]","volume":"129","author":"Harland","year":"2015","journal-title":"Nephron"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s00393-013-1292-9","article-title":"Remission induction in ANCA-associated vasculitis: Follow-up data of the RAVE study","volume":"73","author":"Hellmich","year":"2014","journal-title":"Zeitschrift fur Rheumatologie"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0146|cit146","first-page":"81","article-title":"Outcomes of non-severe relapses in ANCA-associated vasculitis treated with glucocorticoids [abstract no: O61]","volume":"129","author":"Miloslavsky","year":"2015","journal-title":"Nephron"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003232.pub4-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.lpm.2013.02.300","article-title":"Retreatment with rituximab in the RAVE trial [abstract no: P229]","volume":"42","author":"Miloslavsky","year":"2013","journal-title":"Presse Medicale"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003232.pub4-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.lpm.2013.02.302","article-title":"Safety of remission induction with rituximab versus cyclophosphamide in patients 65 and older with severe ANCA-associated vasculitis [abstract no: P231]","volume":"42","author":"Miloslavsky","year":"2013","journal-title":"Presse Medicale"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0149|cit149","first-page":"S315","article-title":"Efficacy of glucocorticoids to treat limited flares in ANCA-associated vasculitis [abstract no: 747]","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0150|cit150","first-page":"S1190","article-title":"Retreatment with rituximab in the Rituximab in ANCA-Associated Vasculitis (RAVE) trial [abstract no: 2782]","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0151|cit151","first-page":"S313","article-title":"Safety of remission induction with rituximab versus cyclophosphamide in patients 65 and older with severe ANCA-associated vasculitis [abstract no: 742]","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0152|cit152","first-page":"S707","article-title":"Primary endpoint failure in the rituximab in ANCA-associated vasculitis trial [abstract no: 1654]","volume":"64","author":"Miloslavsky","year":"2012","journal-title":"Arthritis & Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD003232.pub4-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.38044","article-title":"Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD003232.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0155|cit155","first-page":"S312","article-title":"Serum proteins reflecting inflammation, injury, and repair as biomarkers of disease activity in ANCA-associated vasculitis [abstract no: 792]","volume":"63","author":"Monach","year":"2011","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"e30197","DOI":"10.1371\/journal.pone.0030197","article-title":"Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis","volume":"7","author":"Monach","year":"2012","journal-title":"PLoS One [Electronic Resource]"},{"issue":"12","key":"10.1002\/14651858.CD003232.pub4-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1002\/art.30615","article-title":"Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"63","author":"Monach","year":"2011","journal-title":"Arthritis & Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD003232.pub4-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/annrheumdis-2012-201981","article-title":"Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis","volume":"72","author":"Monach","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13075-015-0778-z","article-title":"Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment","volume":"17","author":"Nasrallah","year":"2015","journal-title":"Arthritis Research & Therapy"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0160|cit160","first-page":"97","article-title":"The role of baseline FCRL5 mRNA expression in predicting response to rituximab (RTX) therapy in patients with granulomatous polyangiitis (GPA) or microscopic polyangiitis (MPA) [abstract no: O86]","volume":"129","author":"Owczarczyk","year":"2015","journal-title":"Nephron"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2014-eular.4265","article-title":"The role of baseline FCRL5 mRNA expression in predicting response to rituximab (RTX) therapy in patients with granulomatous polyangiitis (GPA) or microscopic polyangiitis (MPA) [abstract no: OP0232]","volume":"73","author":"Owczarczyk","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/art.39814","article-title":"Association of serum calprotectin (S100A8\/A9) Level with disease relapse in proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis","volume":"69","author":"Pepper","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2215\/CJN.04160417","article-title":"The utility of urinalysis in determining the risk of renal relapse in ANCA-associated vasculitis","volume":"13","author":"Rhee","year":"2018","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1876539401104010001","article-title":"Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial","volume":"4","author":"Specks","year":"2011","journal-title":"Open Arthritis Journal"},{"issue":"5","key":"10.1002\/14651858.CD003232.pub4-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0166|cit166","first-page":"S310","article-title":"Immunoglobulin concentrations and infection risk among patients with ANCA-associated vasculitis treated with rituximab or cyclophosphamide [abstract no: 789]","volume":"63","author":"Specks","year":"2011","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003232.pub4-BIB0167|cit167","first-page":"65","article-title":"Long-term efficacy and safety results of the RAVE trial [abstract]","volume":"164","author":"Specks","year":"2011","journal-title":"Clinical & Experimental Immunology"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0168|cit168","first-page":"S946","article-title":"Extended follow-up of treatment with rituximab versus cyclophosphamide for remission-induction of ANCA-associated vasculitis: Which subsets are at greatest risk for flare? [abstract no: 2432]","volume":"63","author":"Stone","year":"2011","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD003232.pub4-BIB0169|cit169","first-page":"550","article-title":"Rituximab versus cyclophosphamide for induction of remission of ANCA associated vasculitis: a randomized controlled trial (RAVE) [abstract no: 550]","volume":"60","author":"Stone","year":"2009","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0171|cit171","first-page":"S1085","article-title":"Predictive value of selected markers of inflammation and platelet activation for complete remission in ANCA-associated vasculitis [abstract no: 2567]","volume":"64","author":"Tomasson","year":"2012","journal-title":"Arthritis & Rheumatism"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0172|cit172","first-page":"S769","article-title":"Peripheral CD5+ B-cells in ANCA-associated vasculitis [abstract no: 1754]","volume":"66","author":"Unizony","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/art.38916","article-title":"Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"67","author":"Unizony","year":"2015","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0174|cit174","first-page":"85","article-title":"Comparison of clinicopathologically- and serologically-based classification systems for ANCA-associated vasculitis [abstract no: O67]","volume":"129","author":"Unizony","year":"2015","journal-title":"Nephron"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0175|cit175","first-page":"S775","article-title":"Comparison of clinicopathologically-and serologically-based classification systems for ANCA-associated vasculitis [abstract no: 1766]","volume":"66","author":"Unizony","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD003232.pub4-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD003232.pub4-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/art.41006","article-title":"Disease activity, antineutrophil cytoplasmic antibody type, and lipid levels in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"71","author":"Wallace","year":"2019","journal-title":"Arthritis & Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD003232.pub4-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/acr.23099","article-title":"Effect of disease activity, glucocorticoid exposure, and rituximab on body composition during induction treatment of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"69","author":"Wallace","year":"2017","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0179|cit179","unstructured":"European Vasculitis Study Group (EUVAS) Clinical trial protocol - REMAIN - Randomised trial of prolonged remission-maintenance therapy in systemic vasculitis [Version 4.2: January 2006] www.vasculitis.nl\/media\/documents\/remain.pdf"},{"issue":"10","key":"10.1002\/14651858.CD003232.pub4-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0181|cit181","first-page":"7a","article-title":"Randomized controlled trial of treatment withdrawal in the remission phase of ANCA vasculitis: the REMAIN study [abstract no: TH-OR025]","volume":"26","author":"Karras","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0182|cit182","first-page":"493","article-title":"Treatment of idiopathic acute crescentic glomerulonephritis by immunodepression and plasma-exchanges. A prospective randomised study","volume":"18","author":"Rifle","year":"1981","journal-title":"Proceedings of the European Dialysis & Transplant Association"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1681\/ASN.2011040330","article-title":"Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy","volume":"23","author":"Berden","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0184|cit184","unstructured":"Jayne DR Jones R An international, randomised open label trial comparing a rituximab based regime with a standard cyclophosphamide\/azathioprine regimen in the treatment of active 'generalised' ANCA-associated vasculitis [protocol v1b Nov 2005] www.vasculitis.nl\/media\/documents\/rituxvas.pdf"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003232.pub4-BIB0185|cit185","first-page":"972A","article-title":"Rituximab: a novel remission induction agent in ANCA associated vasculitis: the design of an international, randomised trials (RITUXVAS) [abstract no: PUB647]","volume":"18","author":"Jones","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0186|cit186","unstructured":"Jones R Tervaert J Hauser T Luqmani R Morgan M Peh C Two year follow-up results from a randomised trial of rituximab versus cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS [abstract] Renal Association & British Renal Society Joint Meeting; 2011 Jun 6-9 ; Birmingham, UK 2011 1157"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0187|cit187","unstructured":"Jones R Tervaert JW Hauser T Luqmani R Peh CA Savage C A randomised trial of rituximab versus cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS [abstract no: SA773] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0188|cit188","unstructured":"Jones R Tervaert JW Hauser T Luqmani R Peh CA Savage C Randomised trial of rituximab versus cyclophosphamide for ANCA associated renal vasculitis: RITUXVAS [abstract no: O104] British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21-24; Liverpool, UK 2009"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0189|cit189","unstructured":"Jones R Walsh M Jayne D European Vascular Study Randomised trial of rituximab versus cyclophosphamide for ANCA associated renal vasculitis: RITUXVAS [abstract no: F-FC269] Journal of the American Society of Nephrology 2008 61A"},{"issue":"6","key":"10.1002\/14651858.CD003232.pub4-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003232.pub4-BIB0192|cit192","first-page":"57","article-title":"Two-year follow-up results from a randomized trial of RTX versus CyP for ANCA- associated renal vasculitis: RITUXVAS [abstract]","volume":"164","author":"Jones","year":"2011","journal-title":"Clinical & Experimental Immunology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0193|cit193","first-page":"92A","article-title":"Two-year follow-up results from a randomised trial of rituximab versus cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS [abstract no: SA-FC405]","volume":"21","author":"Jones","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003232.pub4-BIB0194|cit194","first-page":"49","article-title":"Rituximab versus cyclophosphamide in ANCA associated renal vasculitis [abstract no: 087]","volume":"15","author":"Peh","year":"2010","journal-title":"Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0195|cit195","first-page":"930","article-title":"Prevention of relapses of Wegener's granulomatosis by treatment with co-trimoxazole. A placebo controlled trial [abstract]","volume":"6","author":"Stegeman","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group","volume":"335","author":"Stegeman","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/039139889902200205","article-title":"Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study","volume":"22","author":"Stegmayr","year":"1999","journal-title":"International Journal of Artificial Organs"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0198|cit198","unstructured":"Stegmayr BG Almroth G Kurkus J Olander R Sterner G Thysell H Plasma exchange versus immunoadsorption in the treatment of rapidly progressive glomerulonephritis (RPG). A multi-center study [abstract] XXXV Congress of the European Renal Association European Dialysis & Transplant Association; 1998 Jun 6-9; Rimini (Italy) 1998 294"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ndt\/gfq360","article-title":"Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis--a clinical randomized controlled trial","volume":"26","author":"Szpirt","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003232.pub4-BIB0200|cit200","first-page":"182A","article-title":"Long term outcome and prognostic factors in randomized study of plasma exchange and cyclosporin-A in Wegener's granulomatosis [abstract no: A0932]","volume":"10","author":"Szpirt","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003232.pub4-BIB0201|cit201","first-page":"501","article-title":"Plasma exchange and cyclosporin A in Wegner`s granulomatosis a controlled study [abstract]","volume":"19","author":"Szpirt","year":"1996","journal-title":"International Journal of Artificial Organs"},{"issue":"9","key":"10.1002\/14651858.CD003232.pub4-BIB0202|cit202","first-page":"1781","article-title":"Plasma exchange for induction and cyclosporin A for maintenance of remission in Wegener's granulomatosis [abstract no: A2677]","volume":"7","author":"Szpirt","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8717","key":"10.1002\/14651858.CD003232.pub4-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0140-6736(90)92205-V","article-title":"Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre","volume":"336","author":"Tervaert","year":"1990","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0204|cit204","first-page":"194","article-title":"Treatment of ANCA-associated vasculitides: corticosteroids and pulse cyclophosphamide followed by maintenance therapy with methotrexate or azathioprine: a prospective multicenter randomized trial (WEGENT) [abstract no: 102]","volume":"28","author":"Mahr","year":"2005","journal-title":"Kidney & Blood Pressure Research"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0205|cit205","unstructured":"Pagnoux C Mahr A Cohen P Arene JP Hamidou M Guillevin L Treatment of ANCA-associated systemic vasculitis (AASV) with corticosteroids (CS) and pulse cyclophosphamide (CYC), then azathioprine (AZA) or methotrexate (MTX) to maintain remission: interim analysis [abstract] 11th International Vasculitis & ANCA Workshop; 2003 Oct 2-5; Prague, Czech Republic 2003 47"},{"issue":"26","key":"10.1002\/14651858.CD003232.pub4-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0207|cit207","first-page":"80","article-title":"Granulomatosis with polyangiitis or microscopic polyangiitis: long term outcomes of the prospective WEGENT trial comparing azathioprine vs methotrexate for remission maintenance in 126 patients [abstract no: O60]","volume":"129","author":"Puechal","year":"2015","journal-title":"Nephron"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/art.39450","article-title":"Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis","volume":"68","author":"Puechal","year":"2016","journal-title":"Arthritis & Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD003232.pub4-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1136\/ard.2010.131953","article-title":"Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial","volume":"69","author":"Seror","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD003232.pub4-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"611","DOI":"10.7326\/0003-4819-147-9-200711060-00005","article-title":"Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis","volume":"147","author":"Finkielman","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"1 Suppl 52","key":"10.1002\/14651858.CD003232.pub4-BIB0211|cit211","first-page":"S45","article-title":"Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis","volume":"27","author":"Finkielman","year":"2009","journal-title":"Clinical & Experimental Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.bor.0000160777.28259.c2","article-title":"Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies","volume":"17","author":"Goek","year":"2005","journal-title":"Current Opinion in Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD003232.pub4-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-142-8-200505030-00011","article-title":"Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study","volume":"142","author":"Merkel","year":"2005","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2215\/CJN.04160417","article-title":"The utility of urinalysis in determining the risk of renal relapse in ANCA-associated vasculitis","volume":"13","author":"Rhee","year":"2018","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"7","key":"10.1002\/14651858.CD003232.pub4-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/art.21117","article-title":"Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)","volume":"52","author":"Seo","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/art.20938","article-title":"A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis","volume":"52","author":"Stone","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD003232.pub4-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/art.11075","article-title":"Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial","volume":"48","author":"Stone","year":"2003","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/acr.20649","article-title":"Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's)","volume":"64","author":"Tomasson","year":"2012","journal-title":"Arthritis Care & Research"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0197-2456(02)00209-X","article-title":"Design of the Wegener's Granulomatosis Etanercept Trial (WGET)","volume":"23","author":"WGET Research Group","year":"2002","journal-title":"Controlled Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0220|cit220","first-page":"351","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"325","author":"Wegener's Granulomatosis Etanercept Trial Research Group","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003232.pub4-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/art.23561","article-title":"Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis","volume":"59","author":"Wung","year":"2008","journal-title":"Arthritis & Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD003232.pub4-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.amjmed.2005.06.012","article-title":"Herpes zoster in immunocompromised patients: incidence, timing, and risk factors","volume":"118","author":"Wung","year":"2005","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0223|cit223","first-page":"412","article-title":"Effect of initial histology and plasmapheresis treatment on prognosis of RPGN: results of the German prospective randomized multicenter study [abstract no: 947]","volume":"6","author":"Bohler","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/ajkd.2002.29874","article-title":"Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis","volume":"39","author":"Zauner","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"Sept","key":"10.1002\/14651858.CD003232.pub4-BIB0225|cit225","first-page":"172A","article-title":"Ten year follow up after treatment for rapidly progressive glomerulonephritis. Results from the German prospective randomized multicenter study [abstract no: A0918]","volume":"11","author":"Zauner","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/2047-783X-14-S4-265","article-title":"Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement","volume":"14 Suppl 4","author":"Zycinska","year":"2009","journal-title":"European Journal of Medical Research"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003232.pub4-BIB0227|cit227","first-page":"iii164","article-title":"Psychological interventions delivered by allied health professionals (AHPS) can improve quality of life in patients with inactive ANCA associated vasculitis: results from a pilot randomised trial [abstract]","volume":"56","author":"Basu","year":"2017","journal-title":"Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD003232.pub4-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial","volume":"69","author":"Puechal","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD003232.pub4-BIB0229|cit229","first-page":"2201","article-title":"A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (RTX) monotherapy versus the best available treatment in patients with mixed cryoglobulinemia syndrome [abstract]","volume":"62","author":"Vita","year":"2010","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"Vita","year":"2012","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003232.pub4-BIB0231|cit231","first-page":"93","article-title":"A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (RTX) monotherapy versus the best available treatment (BAT) in patients with mixed cryoglobulinemia syndrome [abstract no: OP0120]","volume":"69","author":"Vita","year":"2010","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaut.2015.07.012","article-title":"Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: long-term follow up data of a randomized controlled multicentre study","volume":"63","author":"Quartuccio","year":"2015","journal-title":"Journal of Autoimmunity"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0233|cit233","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2014-eular.3872","article-title":"Rituximab monotherapy of severe HCV-related cryoglobulinemic vasculitis for more than 2 years: follow-up of a randomized controlled multicentre study [abstract no: OP0228]","volume":"73","author":"Quartuccio","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD003232.pub4-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"e023769","DOI":"10.1136\/bmjopen-2018-023769","article-title":"Treatment of fatigue with physical activity and behavioural change support in vasculitis: study protocol for an open-label randomised controlled feasibility study","volume":"8","author":"Harper","year":"2018","journal-title":"BMJ Open"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s10157-005-0396-1","article-title":"Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with crescent formation: an open-label trial to evaluate safety and efficacy","volume":"10","author":"Imai","year":"2006","journal-title":"Clinical & Experimental Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/art.27340","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients","volume":"62","author":"Ribi","year":"2010","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0237|cit237","first-page":"263","article-title":"Treatment of rapidly progressive glomerulonephritis by plasma exchange and methylprednisolone pulses. A prospective randomized trial of cyclophosphamide. Interim analysis. The French Cooperative Group","volume":"337","author":"Rifle","year":"1990","journal-title":"Progress in Clinical & Biological Research"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0238|cit238","first-page":"ii61","article-title":"A randomized controlled trial of mycophenolate mofetil versus cyclophosphamide for induction therapy in ANCA associated systemic vasculitis with renal involvement [abstract]","volume":"27","author":"Chen","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003232.pub4-BIB0239|cit239","first-page":"52","article-title":"A randomized controlled trial of MMF versus CyP for induction therapy in ANCA- AASV with renal involvement [abstract]","volume":"164","author":"Chen","year":"2011","journal-title":"Clinical & Experimental Immunology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD003232.pub4-BIB0240|cit240","first-page":"1296","article-title":"A randomized clinical trial of CCX168, an orally administered C5AR inhibitor for treatment of patients with ANCA-associated vasculitis [abstract no: 978]","volume":"68","author":"Merkel","year":"2016","journal-title":"Arthritis & Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/j.ajkd.2018.02.272","article-title":"C5aR inhibitor avacopan in anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis phase II outcomes of safety, renal parameters, and quality of life [abstract]","volume":"71","author":"Schall","year":"2018","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0242|cit242","first-page":"412A","article-title":"CTLA4-Ig in the treatment of ANCA-associated vasculitis [abstract no: F-PO1308]","volume":"20","author":"Henderson","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0243|cit243","first-page":"744","article-title":"Design of the maintenance of ANCA vasculitis remission by intermittent rituximab dosing based on B cell reconstitution versus a serologic ANCA flare (MAINTANCAVAS) trial [abstract no: SA-PO257]","volume":"28","author":"Cortazar","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0244|cit244","unstructured":"Pagnoux C Cohen P Mahr A Hauser T Mouthon L Arene JP Treatment of Churg Strauss syndrome (CSS) with poor prognosis factor(s): a prospective, randomized, multicenter trial comparing corticosteroids (CS) and 6 vs 12 cyclophosphamide [abstract] 11th International Vasculitis & ANCA Workshop; 2003 Oct 2-5; Prague, Czech Republic 2003 43"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0245|cit245","unstructured":"Guillevin L RATTRAP: Infliximab versus rituximab in systemic necrotizing vasculitides www.clinicaltrials.gov\/ct2\/show\/NCT00307593"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0246|cit246","first-page":"na","article-title":"A randomized phase 3 trial evaluating the safety and efficacy of avacopan in patients with new or relapsing ANCA-associated vasculitis [abstract]","volume":"58","author":"Merkel","year":"2019","journal-title":"Rheumatology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0247|cit247","first-page":"B8","article-title":"Alemtuzumab for relapsing and refractory primary systemic vasculitis: a trial of efficacy and safety (ALEVIATE) [abstract no: TH-PO1160]","volume":"29","author":"Gopaluni","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0140-6736(15)60345-2","article-title":"CD4+CD28- T-cell expansions in ANCA-associated vasculitis and association with arterial stiffness: baseline data from a randomised controlled trial [abstract no: 58]","volume":"385 Suppl 1","author":"Chanouzas","year":"2015","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0249|cit249","first-page":"135","article-title":"CD4+CD28- T-cell expansions in ANCA-associated vasculitis and association with arterial stiffness [abstract no: P51]","volume":"129","author":"Chanouzas","year":"2015","journal-title":"Nephron"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0250|cit250","first-page":"338","article-title":"Valaciclovir to prevent cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial","volume":"17","author":"Chanouzas","year":"2016","journal-title":"Trials [Electronic Resource]"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003232.pub4-BIB0251|cit251","first-page":"282A","article-title":"Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANca Associated VASculitis (CANVAS): results of a randomised controlled clinical trial [abstract no: TH-PO816]","volume":"27","author":"Chanouzas","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003232.pub4-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0140-6736(17)30413-0","article-title":"Role of cytomegalovirus in the expansion of CD4+CD28-T cells in patients with ANCA-associated vasculitis: A proof-of-concept, randomised controlled trial [abstract]","volume":"389","author":"Chanouzas","year":"2017","journal-title":"Lancet"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003232.pub4-BIB0253|cit253","first-page":"iii116","article-title":"Subclinical cytomegalovirus reactivation drives the expansion of cytotoxic endothelial homing T-cells in ANCA associated vasculitis that can be reversed by valaciclovir treatment [abstract]","volume":"56","author":"Chanouzas","year":"2017","journal-title":"Rheumatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0254|cit254","first-page":"na","article-title":"A randomised, double-blind, controlled, mechanistic study of rituximab and belimumab combination therapy in pr3 ANCA-associated vasculitis (COMBIVAS): study protocol [abstract]","volume":"58","author":"McClure","year":"2019","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0255|cit255","unstructured":"Guillevin L Comparison between a long term and a conventional maintenance treatment with rituximab (MAINRITSAN3) www.clinicaltrials.gov\/ct2\/show\/NCT02433522"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0256|cit256","first-page":"4","article-title":"Actualities in the treatment of systemic vasculitis","volume":"2","author":"Buhaescu","year":"2004","journal-title":"BANTAO Journal"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0257|cit257","unstructured":"Couvrat-Desvergnes G Maintaining or stopping immunosuppressive therapy in patients with ANCA vasculitis and end-stage renal disease (MASTER-ANCA) www.clinicaltrials.gov\/show\/NCT03323476"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0258|cit258","first-page":"112","article-title":"Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial","volume":"18","author":"Gopaluni","year":"2017","journal-title":"Trials [Electronic Resource]"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003232.pub4-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.lpm.2013.02.276","article-title":"An international, open-label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis (RITAZAREM) [abstract no: P205]","volume":"42","author":"Jayne","year":"2013","journal-title":"Press Medicale"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003232.pub4-BIB0260|cit260","first-page":"707A","article-title":"RITAZAREM: an international, open label, randomized, controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis [abstract no: SA-PO307]","volume":"23","author":"Jayne","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD003232.pub4-BIB0261|cit261","first-page":"na","article-title":"Rituximab as re-induction therapy in relapsing ANCA-associated vasculitis [abstract no: 18L]","volume":"69","author":"Smith","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003232.pub4-BIB0262|cit262","first-page":"i180","article-title":"RITAZAREM: an international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis [abstract]","volume":"28","author":"Smith","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003232.pub4-BIB0263|cit263","first-page":"110","article-title":"RITAZAREM: an international, open-label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis [abstract no: 13]","volume":"129","author":"Smith","year":"2015","journal-title":"Nephron"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003232.pub4-BIB0264|cit264","first-page":"iii150","article-title":"RITAZAREM: An international, open-label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis [abstract]","volume":"56","author":"Smith","year":"2017","journal-title":"Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD003232.pub4-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.11801018","article-title":"Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial","volume":"14","author":"Tuin","year":"2019","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003232.pub4-BIB0266|cit266","first-page":"iii16","article-title":"Mycophenolate mofetil versus cyclophosphamide for the induction of remission in non-life-threatening relapses of PR3 and MPOANCA associated vasculitis [abstract]","volume":"56","author":"Tuin","year":"2017","journal-title":"Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD003232.pub4-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000167998","article-title":"Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis","volume":"9","author":"Bolton","year":"1989","journal-title":"American Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003232.pub4-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jama.298.6.655","article-title":"Treatment of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"298","author":"Bosch","year":"2007","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD003232.pub4-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/ndt\/16.10.2018","article-title":"The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review","volume":"16","author":"Groot","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003232.pub4-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","article-title":"Wegener's granulomatosis: studies in eighteen patients and a review of the literature","volume":"52","author":"Fauci","year":"1973","journal-title":"Medicine"},{"issue":"7650","key":"10.1002\/14651858.CD003232.pub4-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD003232.pub4-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7414","key":"10.1002\/14651858.CD003232.pub4-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0275|cit275","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"7","key":"10.1002\/14651858.CD003232.pub4-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"Qjm"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0277|cit277","first-page":"341","article-title":"Renal and systemic vasculitis","volume-title":"Comprehensive clinical nephrology","author":"Jennette","year":"2003"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/BOR.0b013e3282f16c0a","article-title":"New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"20","author":"Jennette","year":"2008","journal-title":"Current Opinion in Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/kisup.2012.26","article-title":"Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney International Supplements"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1440-1797.2001.00052.x","article-title":"Is there a role for plasma exchange in rapidly progressive glomerulonephritis?","volume":"6","author":"Kerr","year":"2001","journal-title":"Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD003232.pub4-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/rheumatology\/kem146a","article-title":"BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis","volume":"46","author":"Lapraik","year":"2007","journal-title":"Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000188012","article-title":"Rapidly progressive glomerulonephritis: what should be first-line therapy?","volume":"67","author":"Levey","year":"1994","journal-title":"Nephron"},{"issue":"6","key":"10.1002\/14651858.CD003232.pub4-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7962","key":"10.1002\/14651858.CD003232.pub4-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0140-6736(76)93089-0","article-title":"Immunosuppression and plasma exchange in the treatment of Goodpasture's syndrome","volume":"1","author":"Lockwood","year":"1976","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1111\/j.1440-1797.2008.00995.x","article-title":"The CARI guidelines. Induction and maintenance therapy in ANCA-associated systemic vasculitis","volume":"13 Suppl 2","author":"Menahem","year":"2008","journal-title":"Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9054","key":"10.1002\/14651858.CD003232.pub4-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0140-6736(05)60198-5","article-title":"Mycophenolate mofetil for systemic vasculitis and IgA nephropathy","volume":"349","author":"Nowack","year":"1997","journal-title":"Lancet"},{"issue":"5 Suppl 51","key":"10.1002\/14651858.CD003232.pub4-BIB0290|cit290","first-page":"S94","article-title":"Mortality in systemic vasculitis: a systematic review","volume":"26","author":"Phillip","year":"2008","journal-title":"Clinical & Experimental Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/oxfordjournals.ndt.a091855","article-title":"Plasma exchange and immunosuppression for rapidly progressive glomerulonephritis: prognosis and complications","volume":"4","author":"Rondeau","year":"1989","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9051","key":"10.1002\/14651858.CD003232.pub4-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0140-6736(97)80118-3","article-title":"Primary systemic vasculitis","volume":"349","author":"Savage","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0293|cit293","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0294|cit294","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD003232.pub4-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.amjmed.2004.02.030","article-title":"The antineutrophil cytoplasmic antibody-associated vasculitides","volume":"117","author":"Seo","year":"2004","journal-title":"American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003232.pub4-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00041552-200103000-00009","article-title":"Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"10","author":"Tervaert","year":"2001","journal-title":"Current Opinion in Nephrology & Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD003232.pub4-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1053\/j.ajkd.2010.10.049","article-title":"Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis","volume":"57","author":"Walsh","year":"2011","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0298|cit298","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003232","article-title":"Treatment for renal vasculitis and Goodpasture's disease in adults","author":"Walters","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD003232.pub4-BIB0299|cit299","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003232.pub2","article-title":"Interventions for renal vasculitis in adults","author":"Walters","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003232.pub4-BIB0300|cit300","first-page":"12","article-title":"Walters GD, Willis NS, Craig JC","volume":"11","author":"Interventions for renal vasculitis in adults.","year":"2010","journal-title":"BMC Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003232.pub4-BIB0301|cit301","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003232.pub3","article-title":"Interventions for renal vasculitis in adults","author":"Walters","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003232.pub4\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T23:20:28Z","timestamp":1665444028000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003232.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":301,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003232.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]}}}